<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681757</url>
  </required_header>
  <id_info>
    <org_study_id>15-1828</org_study_id>
    <nct_id>NCT02681757</nct_id>
  </id_info>
  <brief_title>Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns</brief_title>
  <official_title>A Comparison of Mepitel Ag vs Antibiotic Ointment When Used With the Soft Cast Technique for the Treatment of Pediatric Hand and Foot Burns, a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare Mepitel Ag to Triple antibiotic ointment impregnated
      Adaptic gauze when used with the soft cast technique to assess overall time to healing, yeast
      infection rate and parents perception of pain level at time of dressing change on a scale of
      1-10. The hypothesis is that Mepitel Ag in combination with the soft cast technique improves
      wound healing in pediatric partial to deep partial thickness hand and foot burns by
      decreasing the length of healing time, decreasing the risk of yeast infection, and decreasing
      pain associated with dressing changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is currently no gold standard dressing when it comes to treating hand or foot burns,
      specifically in the pediatric population. Our institution currently utilizes the soft cast
      technique (SCT) on all of our hand and foot burns. The SCT uses triple antibiotic ointment
      (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast
      material, and coban. This dressing is applied one to two times during the first 2 weeks post
      injury. The underlying dressing is changed to nystatin impregnated Adaptic gauze, kling or
      kerlex, cast padding, gypsoma plaster, soft cast material, and coban for the remainder of
      treatment time or until surgery is indicated for debridement and grafting of wounds. The soft
      cast technique provides optimal positioning of the wounded hand or foot, allows for a moist
      wound environment, and offers protection of the injured extremity as the wound heals. The
      literature reveals that early surgical intervention performed in the first 7 to 10 days post
      injury has been shown to help achieve maximal function while decreasing the risk of
      hypertrophic scar formation.

      A review of the current literature demonstrates silver sulfadiazine (SSD) to be the most
      frequently used dressing for burn wound treatment in many clinics nationwide. The use of SSD
      is associated with once to twice daily painful dressing changes and wound exposure that &quot;may
      lead to disruption of newly formed epithelium, wound colonization, subsequent wound infection
      and deepening of the burn&quot;. One major benefit of the SCT is the reduction in required
      dressing changes, as the soft cast can stay in place for 7-10 days while maintaining optimal
      hand or foot positioning. This eliminates the need for painful dressing changes. Occasionally
      in our clinic, we have observed yeast infections under the soft cast when patients require
      serial casting. Other complications include occasional drying out of the adaptic gauze, which
      leads to painful dressing removal and interruption of the newly epithelialized wound bed.
      Mepitel Ag, a new soft silicone dressing produced by Molnlycke Health Care, combines Safetac
      technology with a silver compound to provide a broad spectrum of antimicrobial coverage,
      lasting up to 8 days, while minimizing damage to the new epithelium and creating a moist
      wound environment. The safetac technology &quot;protects the wound and the skin. It prevents an
      outer dressing from sticking to the wound, therefore minimizes trauma and pain&quot;. The highly
      pliable nature and antimicrobial properties of the dressing make it an ideal alternative to
      TAO and SSD for the treatment of pediatric partial to deep partial thickness hand and foot
      burns.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">September 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Wound Appearance From Initial Injury Until Wound Healed</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Burn will be evaluated every 3-7 days from date of randomization for up to 21 days (End of Study) after application of Mepitel Ag or triple antibiotic ointment impregnated Adaptic gauze to determine if the burn healed or not.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pain Level</measure>
    <time_frame>Up to 21 days from date of surgery</time_frame>
    <description>Subject will be evaluated at first post-operative follow up visit ranging from date of surgery up to 21 days (End of Study) for level of pain at time of dressing change based on FLACC scale and calculated per Nurse and parent perceived level of patient pain. &quot;The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Yeast Infection in Burn Wound</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Subject will be evaluated every 3-7 days from date of randomization for up to 21 days (End of Study) for clinically observed evidence of yeast infection from visible wound inspection at time of dressing change, i.e.: foul yeast odor, red erythematous rash.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Control- triple antibiotic ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Variable- mepitel Ag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>triple antibiotic ointment dressing</intervention_name>
    <description>used for control group under soft cast</description>
    <arm_group_label>Control- triple antibiotic ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepitel Ag</intervention_name>
    <description>used for variable/experimental group under soft cast</description>
    <arm_group_label>Variable- mepitel Ag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children's Hospital Colorado burn patients

          -  Age 31 days to 18 years

          -  Newly diagnosed partial to deep partial or full thickness hand or foot burns,
             including bilateral or unilateral injury

        Exclusion Criteria:

          -  silver allergy

          -  silicone allergy

          -  electrical burn

          -  chemical burn

          -  past medical history of immunodeficiency disorders such as diabetes mellitus

          -  h/o AIDs or HIV,

          -  h/o pregnant women

          -  prisoners

          -  decisionally challenged
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Days</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Moulton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorad, Childrens Hospital Colorado</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abu-Sittah GS, El Khatib AM, Dibo SA. Thermal injury to the hand: review of the literature. Ann Burns Fire Disasters. 2011 Dec 31;24(4):175-85.</citation>
    <PMID>22639560</PMID>
  </reference>
  <reference>
    <citation>Barret JP, Herndon DN. Plantar burns in children: epidemiology and sequelae. Ann Plast Surg. 2004 Nov;53(5):462-4.</citation>
    <PMID>15502462</PMID>
  </reference>
  <reference>
    <citation>Briggs SL, Taylor A, Lansdown AB. Clinical perspective on silicone dressings and wound management. J Wound Care. 2008 Aug;17(8):364-5; author reply 365-6.</citation>
    <PMID>18754199</PMID>
  </reference>
  <reference>
    <citation>Brown M, Dalziel SR, Herd E, Johnson K, Wong She R, Shepherd M. A Randomized Controlled Study of Silver-Based Burns Dressing in a Pediatric Emergency Department. J Burn Care Res. 2016 Jul-Aug;37(4):e340-7. doi: 10.1097/BCR.0000000000000273.</citation>
    <PMID>26171678</PMID>
  </reference>
  <reference>
    <citation>Bugmann P, Taylor S, Gyger D, Lironi A, Genin B, Vunda A, La Scala G, Birraux J, Le Coultre C. A silicone-coated nylon dressing reduces healing time in burned paediatric patients in comparison with standard sulfadiazine treatment: a prospective randomized trial. Burns. 1998 Nov;24(7):609-12.</citation>
    <PMID>9882058</PMID>
  </reference>
  <reference>
    <citation>Choi M, Armstrong MB, Panthaki ZJ. Pediatric hand burns: thermal, electrical, chemical. J Craniofac Surg. 2009 Jul;20(4):1045-8. Review.</citation>
    <PMID>19634213</PMID>
  </reference>
  <reference>
    <citation>Duteille F, Jeffery SL. A phase II prospective, non-comparative assessment of a new silver sodium carboxymethylcellulose (AQUACEL(®) Ag BURN) glove in the management of partial thickness hand burns. Burns. 2012 Nov;38(7):1041-50. doi: 10.1016/j.burns.2012.05.001. Epub 2012 Jun 5.</citation>
    <PMID>22677163</PMID>
  </reference>
  <reference>
    <citation>Feldmann ME, Evans J, O SJ. Early management of the burned pediatric hand. J Craniofac Surg. 2008 Jul;19(4):942-50. doi: 10.1097/SCS.0b013e318175f38d. Review.</citation>
    <PMID>18650716</PMID>
  </reference>
  <reference>
    <citation>Gee Kee E, Kimble RM, Cuttle L, Stockton K. Comparison of three different dressings for partial thickness burns in children: study protocol for a randomised controlled trial. Trials. 2013 Nov 25;14:403. doi: 10.1186/1745-6215-14-403.</citation>
    <PMID>24274190</PMID>
  </reference>
  <reference>
    <citation>Johnson J, Silverberg R. Serial casting of the lower extremity to correct contractures during the acute phase of burn care. Phys Ther. 1995 Apr;75(4):262-6. Erratum in: Phys Ther 1995 Jul;75(7):640.</citation>
    <PMID>7899484</PMID>
  </reference>
  <reference>
    <citation>Meuleneire F, Rucknagel H. Soft Silicone dressings made easy. Wounds International 2013.</citation>
  </reference>
  <reference>
    <citation>Mitura K, Osłowska J, Mitura A. A Change of Traditional Method of Treatment of Partial Thickness Burn with Hydrofibre Dressings. Pol Przegl Chir. 2015 Feb;87(2):91-6. doi: 10.1515/pjs-2015-0025.</citation>
    <PMID>26146101</PMID>
  </reference>
  <reference>
    <citation>White R, Morris C. Mepitel: a non-adherent wound dressing with Safetac technology. Br J Nurs. 2009 Jan 8-21;18(1):58-64. Review.</citation>
    <PMID>19127235</PMID>
  </reference>
  <reference>
    <citation>Toussaint J, Chung WT, Osman N, McClain SA, Raut V, Singer AJ. Topical antibiotic ointment versus silver-containing foam dressing for second-degree burns in swine. Acad Emerg Med. 2015 Aug;22(8):927-33. doi: 10.1111/acem.12723. Epub 2015 Jul 22.</citation>
    <PMID>26202791</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <results_first_submitted>November 7, 2019</results_first_submitted>
  <results_first_submitted_qc>December 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric hand burn</keyword>
  <keyword>pediatric foot burn</keyword>
  <keyword>mepitel Ag</keyword>
  <keyword>soft cast technique for burn wound heaing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02681757/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control- Triple Antibiotic Ointment</title>
          <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
triple antibiotic ointment dressing: used for control group under soft cast</description>
        </group>
        <group group_id="P2">
          <title>Variable- Mepitel Ag</title>
          <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
Mepitel Ag: used for variable/experimental group under soft cast</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control- Triple Antibiotic Ointment</title>
          <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
triple antibiotic ointment dressing: used for control group under soft cast</description>
        </group>
        <group group_id="B2">
          <title>Variable- Mepitel Ag</title>
          <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
Mepitel Ag: used for variable/experimental group under soft cast</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="1.3" upper_limit="6.5"/>
                    <measurement group_id="B2" value="1.6" lower_limit="1.1" upper_limit="3.0"/>
                    <measurement group_id="B3" value="1.8" lower_limit="1.1" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Wound Appearance From Initial Injury Until Wound Healed</title>
        <description>Burn will be evaluated every 3-7 days from date of randomization for up to 21 days (End of Study) after application of Mepitel Ag or triple antibiotic ointment impregnated Adaptic gauze to determine if the burn healed or not.</description>
        <time_frame>Up to 21 days</time_frame>
        <population>Some participants had multiple burns. We investigated all burns.</population>
        <group_list>
          <group group_id="O1">
            <title>Control- Triple Antibiotic Ointment</title>
            <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
triple antibiotic ointment dressing: used for control group under soft cast</description>
          </group>
          <group group_id="O2">
            <title>Variable- Mepitel Ag</title>
            <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
Mepitel Ag: used for variable/experimental group under soft cast</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Wound Appearance From Initial Injury Until Wound Healed</title>
          <description>Burn will be evaluated every 3-7 days from date of randomization for up to 21 days (End of Study) after application of Mepitel Ag or triple antibiotic ointment impregnated Adaptic gauze to determine if the burn healed or not.</description>
          <population>Some participants had multiple burns. We investigated all burns.</population>
          <units>Burns</units>
          <param>Count of Units</param>
          <units_analyzed>Burns</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Burns</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Pain Level</title>
        <description>Subject will be evaluated at first post-operative follow up visit ranging from date of surgery up to 21 days (End of Study) for level of pain at time of dressing change based on FLACC scale and calculated per Nurse and parent perceived level of patient pain. &quot;The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.&quot;</description>
        <time_frame>Up to 21 days from date of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control- Triple Antibiotic Ointment</title>
            <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
triple antibiotic ointment dressing: used for control group under soft cast</description>
          </group>
          <group group_id="O2">
            <title>Variable- Mepitel Ag</title>
            <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
Mepitel Ag: used for variable/experimental group under soft cast</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pain Level</title>
          <description>Subject will be evaluated at first post-operative follow up visit ranging from date of surgery up to 21 days (End of Study) for level of pain at time of dressing change based on FLACC scale and calculated per Nurse and parent perceived level of patient pain. &quot;The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Yeast Infection in Burn Wound</title>
        <description>Subject will be evaluated every 3-7 days from date of randomization for up to 21 days (End of Study) for clinically observed evidence of yeast infection from visible wound inspection at time of dressing change, i.e.: foul yeast odor, red erythematous rash.</description>
        <time_frame>Up to 21 days</time_frame>
        <population>The unit of observation is a single burn, not an individual patient. This outcome is number of yeast infections per burn dressing group.</population>
        <group_list>
          <group group_id="O1">
            <title>Control- Triple Antibiotic Ointment</title>
            <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
triple antibiotic ointment dressing: used for control group under soft cast</description>
          </group>
          <group group_id="O2">
            <title>Variable- Mepitel Ag</title>
            <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
Mepitel Ag: used for variable/experimental group under soft cast</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Yeast Infection in Burn Wound</title>
          <description>Subject will be evaluated every 3-7 days from date of randomization for up to 21 days (End of Study) for clinically observed evidence of yeast infection from visible wound inspection at time of dressing change, i.e.: foul yeast odor, red erythematous rash.</description>
          <population>The unit of observation is a single burn, not an individual patient. This outcome is number of yeast infections per burn dressing group.</population>
          <units>burns</units>
          <param>Number</param>
          <units_analyzed>Burns</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Burns</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control- Triple Antibiotic Ointment</title>
          <description>triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
triple antibiotic ointment dressing: used for control group under soft cast</description>
        </group>
        <group group_id="E2">
          <title>Variable- Mepitel Ag</title>
          <description>mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
Mepitel Ag: used for variable/experimental group under soft cast</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Choi Young Mee MD</name_or_title>
      <organization>Children's Hospital Colorado</organization>
      <phone>7207770859</phone>
      <email>youngmeeyoungmee@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

